en
Scientific article
Open access
French

Prise en charge de la carcinose péritonéale par chirurgie cytoréductive et chimiothérapie hyperthermique intrapéritonéale

Published inRevue médicale suisse, vol. 12, no. 523, p. 1190-1194
Publication date2016
Abstract

In 2016, peritoneal carcinomatosis can be considered as a chronic disease that can be treated and sometimes cured. Hyperthermic Intra PEritoneal Chemotherapy (HIPEC) is a procedure developed in the eighties. Combined with CytoReductive (CR) surgery, this protocol underwent a considerable expansion in Washington Cancer Institute. CR combined with HIPEC was demonstrated to be the only curative treatment for PseudoMyxoma Peritonei syndrome (PMP). It is actually approved in the management of peritoneal carcinomatosis of ovarian, colorectal, or peritoneal primitive (mesothelioma) origin but is still studied for gastric cancer. CR/HIPEC is associated with an important mortality and morbidity. This article takes stock of indications to CR/HIPEC.

Keywords
  • Chemotherapy
  • Cancer
  • Regional Perfusion
  • Cytoreduction Surgical Procedures
  • Humans
  • Hyperthermia
  • Induced
  • Peritoneal Neoplasms/therapy
Citation (ISO format)
BALAPHAS, Alexandre et al. Prise en charge de la carcinose péritonéale par chirurgie cytoréductive et chimiothérapie hyperthermique intrapéritonéale. In: Revue médicale suisse, 2016, vol. 12, n° 523, p. 1190–1194.
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal1660-9379
646views
256downloads

Technical informations

Creation09/13/2017 11:36:00 AM
First validation09/13/2017 11:36:00 AM
Update time03/15/2023 2:16:43 AM
Status update03/15/2023 2:16:42 AM
Last indexation01/17/2024 1:13:59 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack